CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic...
Phase 1
San Francisco, California, United States and 1 other location
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
San Francisco, California, United States and 15 other locations
in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreat...
Phase 1, Phase 2
San Francisco, California, United States and 11 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
San Francisco, California, United States and 38 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
San Francisco, California, United States and 41 other locations
with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors...
Phase 2
San Francisco, California, United States and 2 other locations
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...
Phase 2
San Jose, California, United States and 71 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
San Francisco, California, United States and 65 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec ...
Phase 1, Phase 2
Stanford, California, United States and 10 other locations
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....
Phase 1, Phase 2
San Francisco, California, United States and 77 other locations
Clinical trials
Research sites
Resources
Legal